Marketplace Storefronts in the April 2026 Batch

Updated August 25, 2026

Two recipients in the FDA's March 31, 2026 warning-letter batch, FormPour and Guangzhou Huli Technology Co., Ltd. dba Fantasy Face, sold through eBay storefronts rather than standalone websites. Each letter opens on the agency's review of the eBay store, applies 21 CFR 201.128, and is copied to a named regulatory-policy contact at eBay.

The two records

Each letter has its own record page in this index: FormPour, letter 722215 and Fantasy Face, letter 722228.

The letters open on the storefront

The five other letters in the batch begin with the agency's review of a company website. These two begin differently: each states, in its opening passage, that FDA reviewed the recipient's eBay store — the review object is the marketplace storefront itself, identified by its store URL. Nothing else about the opening changes. The store's listings were read the way a company's own product pages are read elsewhere in the batch, and the review had run since December 2025, roughly three months before the letters were signed.

The statute reading is the batch's reading

Both letters apply the same legal chain as the rest of the seven: the products are drugs under FDCA §201(g)(1), 21 U.S.C. 321(g)(1); new drugs under §201(p), 321(p); introduced in violation of §301(d), 331(d) and §505(a), 355(a). Intended use is determined under 21 CFR 201.128 — the regulation under which claim evidence from listing pages establishes what a product is for. That determination attached to marketplace listings exactly as it attached to standalone-site product pages. On the record of these two letters, selling through a marketplace is not a separate lane with a separate standard.

The platform was put on notice

Both letters carry a cc line to a named regulatory-policy contact at eBay — an individual identified by name and role at the platform, not a general corporate address. The agency did not only write to the sellers; it notified the marketplace that hosts them, in the same document. This index records the cc as a role; the practical reading is that a marketplace storefront's compliance record now travels to the platform at the same moment it becomes public.

What the two records establish

Taken together, the FormPour and Fantasy Face letters document three things. A marketplace storefront is reviewed as the vendor's own site. The 201.128 intended-use analysis applies to its listings unchanged. And the platform receives the letter alongside the seller. The products at issue also extended beyond vialed compounds — a microneedle patch product and an oral-solution product — a scope question documented separately at patch and oral products in the enforcement record.

Context

These are two of seven letters dated March 31, 2026 and posted April 7, 2026; the full roster is tabulated at the March 31, 2026 batch record, and every recipient entity holds an entry in the vendor index. No confirmed direct FDA URL for letter 722215 or 722228 has been captured by this index; both letters are retrievable from the FDA warning-letters database by recipient name. No response, close-out, or follow-on action has been found for either recipient as of this page's dateline — the outcome of both letters is unknown.

Sources

1. FDA Warning Letters database (retrieves both letters by recipient name). fda.gov
2. Policy Canary analysis of the March 31, 2026 batch. policycanary.io
3. Partnership for Safe Medicines, summary of the seven letters (posted April 7, 2026). safemedicines.org

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.